Skip to content

MRL in the Upper Extremity

Magnetic Resonance Lymphography in Upper Extremity Lymphedema and Healthy Subjects

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04575636
Enrollment
20
Registered
2020-10-05
Start date
2020-09-10
Completion date
2023-08-31
Last updated
2023-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphedema of Upper Limb

Brief summary

Objective: The aim of this study is to examine the feasibility and applicability of the MRL protocol for the upper extremity in Maastricht University Medical Center, and to examine the differences of the lymphatic system between lymphedema patients and healthy volunteers. Study design: An explorative study of an MRL protocol for the upper extremity in Maastricht University Medical Center+. Study population: There are two study groups. The first group (n=10) consists of patients with secondary lymphedema in the upper extremity. The second group (n=10) consists of healthy volunteers. Intervention (if applicable): All participants will undergo an MRL examination with the same protocol, developed in a previous 'proof of principle' study, in the Maastricht University Medical Center+. After localizer scans, a T2-weighted sequence is used. Then a T1-weighted sequence will be made before the injection of contrast. After the injection of the contrast agent a T1-weighted sequences of the upper and lower arm are performed alternately. Main study parameters/endpoints: The primary outcome is to determine the feasibility and applicability of the MRL protocol by evaluating the images of the upper extremity in patients with secondary lymphedema and healthy subjects. The secondary outcome is to assess the value of MRL in staging lymphedema.

Interventions

DIAGNOSTIC_TESTMagnetic Resonance Lymphography

Magnetic Resonance Lymphography using Siemens 3T MRI unit and Gadobutrol as a contrast agent to visualize the lymphatic system

Sponsors

Maastricht University Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

* 18 years or older * informed consent * BMI \< 30 kg/m2 Group A: \- Secondary lymphedema in the upper extremity Group B: \- Healthy volunteers

Exclusion criteria

* Active skin infection/erysipelas in the arm. * Known allergy for a contrast agent * History of surgical intervention in the arm. * Contraindications for MRI with contrast; pregnancy, metals, prostheses, renal insufficiency, claustrophobia * Active cancer * Distant metastases

Design outcomes

Primary

MeasureTime frameDescription
feasiblity of Magentic Resonance Lymphography (MRL) of the arm by evaluating the MRL output images0.5 hours per participantDescribing lymphatic vessel characteristics in terms of size, diameter and course, and lymphedema symptoms such as dermal backflow or obstruction

Secondary

MeasureTime frameDescription
lymphedema staging by evaluating the MRL output images0.5 hours per participantDescribing lymphedema stage, based on lymphatic vessel charasteristics and lymphedema symptoms as found at primary outcome. This is compared with ISL (clinical) lymphedema stage and ICG lymphography stage.

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026